The $95 billion biotech Gilead Sciences is accelerating its effort to test a promising drug to treat COVID-19, the disease caused by the spreading coronavirus outbreak.
Gilead announced on Wednesday plans for two late-stage clinical trials. The studies will assess different doses and treatment courses of the experimental antiviral medication remdesivir in about 1,000 patients with COVID-19.
A sense of urgency has been placed on the drug industry to identify and develop vaccines and treatments to halt the coronavirus outbreak that has killed more than 2,700 people and sickened more than 81,000. Since it originated in China, the virus has spread to at least 40 other countries, encompassing six continents.
The efforts build on ongoing tests of the drug in China and the US. Gilead said these new studies would start enrolling patients in March “across Asian countries, as well as other countries globally with high numbers of diagnosed cases.”
Gilead said it would likely get the first results from some of those earlier studies in April.
The National Institutes of Health’s infectious-disease unit recently started a trial of remdesivir in the US with COVID-19 patients.
“Gilead’s primary focus is on rapidly determining the safety and efficacy of remdesivir as a potential treatment for COVID-19, and this complementary array of studies helps to give us a more expansive breadth of data globally on the drug’s profile in a short amount of time,” Merdad Parsey, Gilead’s chief medical officer, said in a statement.
Health officials and experts have emphasized the potential for remdesivir. A single case reported in The New England Journal of Medicine stirred initial excitement about the drug’s promise.
“There is only one drug right now that we think may have real efficacy and that’s remdesivir,” Bruce Aylward, an assistant director-general of the World Health Organization, said at a recent press conference, CNN reported.